The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma

Mahmut Yasen, Kazunori Kajino, Sayaka Kano, Hiroshi Tobita, Junji Yamamoto, Takeshi Uchiumi, Shigeyuki Kon, Masahiro Maeda, Gulanbar Obulhasim, Shigeki Arii, Okio Hino

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: The development of hepatocellular carcinoma is associated with the chronic inflammation of the liver caused by various factors such as hepatitis B or C virus infection. Previously, we reported DNA binding protein A (dbpA) as a candidate molecule that can accelerate inflammation-induced hepatocarcinogenesis. DbpA belongs to the Y-box binding protein family, and Y-box binding protein-1 (YB-1), the prototype member of this family, is reported to be a prognostic marker of malignant diseases other than hepatocellular carcinoma. The purpose of this study is to examine the significance of the expression of dbpA or of the T-to-G transversion in the dbpA promoter region, which enhances the promoter activity in vitro, for the progression of hepatocellular carcinoma. Experimental Design: We studied the expression of dbpA (as well as of YB-1) in 82 formalin-fixed hepatocellular carcinoma tissues by immunohistochemistry and determined the sequence of the dbpA promoter region in 42 frozen hepatocellular carcinoma tissues. We examined the relationship between these findings and the clinicopathologic factors of hepatocellular carcinoma patients. Results: DbpA expression was associated with the advanced stages of hepatocellular carcinoma, and the cases with the nuclear dbpA expression had a poor prognosis. DbpA contributed more significantly to this association than YB-1. Furthermore, the T-to-G transversion in the dbpA promoter region was related to the nuclear localization of dbpA. Conclusion: DbpA was a more significant prognostic marker of hepatocellular carcinoma than YB-1. The T-to-G transversion in the dbpA promoter region was suggested to be a predisposing factor for the progression of hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)7354-7361
Number of pages8
JournalClinical Cancer Research
Volume11
Issue number20
DOIs
Publication statusPublished - Oct 15 2005

Fingerprint

Y-Box-Binding Protein 1
Staphylococcal Protein A
DNA-Binding Proteins
Hepatocellular Carcinoma
Carrier Proteins
Up-Regulation
Genetic Promoter Regions
Inflammation
Virus Diseases
Nuclear Proteins
Hepatitis B virus
Hepacivirus
Causality
Formaldehyde
Research Design
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. / Yasen, Mahmut; Kajino, Kazunori; Kano, Sayaka; Tobita, Hiroshi; Yamamoto, Junji; Uchiumi, Takeshi; Kon, Shigeyuki; Maeda, Masahiro; Obulhasim, Gulanbar; Arii, Shigeki; Hino, Okio.

In: Clinical Cancer Research, Vol. 11, No. 20, 15.10.2005, p. 7354-7361.

Research output: Contribution to journalArticle

Yasen, Mahmut ; Kajino, Kazunori ; Kano, Sayaka ; Tobita, Hiroshi ; Yamamoto, Junji ; Uchiumi, Takeshi ; Kon, Shigeyuki ; Maeda, Masahiro ; Obulhasim, Gulanbar ; Arii, Shigeki ; Hino, Okio. / The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 20. pp. 7354-7361.
@article{cb3aa6e441b041779cb7f07a5a19b5e5,
title = "The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma",
abstract = "Purpose: The development of hepatocellular carcinoma is associated with the chronic inflammation of the liver caused by various factors such as hepatitis B or C virus infection. Previously, we reported DNA binding protein A (dbpA) as a candidate molecule that can accelerate inflammation-induced hepatocarcinogenesis. DbpA belongs to the Y-box binding protein family, and Y-box binding protein-1 (YB-1), the prototype member of this family, is reported to be a prognostic marker of malignant diseases other than hepatocellular carcinoma. The purpose of this study is to examine the significance of the expression of dbpA or of the T-to-G transversion in the dbpA promoter region, which enhances the promoter activity in vitro, for the progression of hepatocellular carcinoma. Experimental Design: We studied the expression of dbpA (as well as of YB-1) in 82 formalin-fixed hepatocellular carcinoma tissues by immunohistochemistry and determined the sequence of the dbpA promoter region in 42 frozen hepatocellular carcinoma tissues. We examined the relationship between these findings and the clinicopathologic factors of hepatocellular carcinoma patients. Results: DbpA expression was associated with the advanced stages of hepatocellular carcinoma, and the cases with the nuclear dbpA expression had a poor prognosis. DbpA contributed more significantly to this association than YB-1. Furthermore, the T-to-G transversion in the dbpA promoter region was related to the nuclear localization of dbpA. Conclusion: DbpA was a more significant prognostic marker of hepatocellular carcinoma than YB-1. The T-to-G transversion in the dbpA promoter region was suggested to be a predisposing factor for the progression of hepatocellular carcinoma.",
author = "Mahmut Yasen and Kazunori Kajino and Sayaka Kano and Hiroshi Tobita and Junji Yamamoto and Takeshi Uchiumi and Shigeyuki Kon and Masahiro Maeda and Gulanbar Obulhasim and Shigeki Arii and Okio Hino",
year = "2005",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-05-1027",
language = "English",
volume = "11",
pages = "7354--7361",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma

AU - Yasen, Mahmut

AU - Kajino, Kazunori

AU - Kano, Sayaka

AU - Tobita, Hiroshi

AU - Yamamoto, Junji

AU - Uchiumi, Takeshi

AU - Kon, Shigeyuki

AU - Maeda, Masahiro

AU - Obulhasim, Gulanbar

AU - Arii, Shigeki

AU - Hino, Okio

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Purpose: The development of hepatocellular carcinoma is associated with the chronic inflammation of the liver caused by various factors such as hepatitis B or C virus infection. Previously, we reported DNA binding protein A (dbpA) as a candidate molecule that can accelerate inflammation-induced hepatocarcinogenesis. DbpA belongs to the Y-box binding protein family, and Y-box binding protein-1 (YB-1), the prototype member of this family, is reported to be a prognostic marker of malignant diseases other than hepatocellular carcinoma. The purpose of this study is to examine the significance of the expression of dbpA or of the T-to-G transversion in the dbpA promoter region, which enhances the promoter activity in vitro, for the progression of hepatocellular carcinoma. Experimental Design: We studied the expression of dbpA (as well as of YB-1) in 82 formalin-fixed hepatocellular carcinoma tissues by immunohistochemistry and determined the sequence of the dbpA promoter region in 42 frozen hepatocellular carcinoma tissues. We examined the relationship between these findings and the clinicopathologic factors of hepatocellular carcinoma patients. Results: DbpA expression was associated with the advanced stages of hepatocellular carcinoma, and the cases with the nuclear dbpA expression had a poor prognosis. DbpA contributed more significantly to this association than YB-1. Furthermore, the T-to-G transversion in the dbpA promoter region was related to the nuclear localization of dbpA. Conclusion: DbpA was a more significant prognostic marker of hepatocellular carcinoma than YB-1. The T-to-G transversion in the dbpA promoter region was suggested to be a predisposing factor for the progression of hepatocellular carcinoma.

AB - Purpose: The development of hepatocellular carcinoma is associated with the chronic inflammation of the liver caused by various factors such as hepatitis B or C virus infection. Previously, we reported DNA binding protein A (dbpA) as a candidate molecule that can accelerate inflammation-induced hepatocarcinogenesis. DbpA belongs to the Y-box binding protein family, and Y-box binding protein-1 (YB-1), the prototype member of this family, is reported to be a prognostic marker of malignant diseases other than hepatocellular carcinoma. The purpose of this study is to examine the significance of the expression of dbpA or of the T-to-G transversion in the dbpA promoter region, which enhances the promoter activity in vitro, for the progression of hepatocellular carcinoma. Experimental Design: We studied the expression of dbpA (as well as of YB-1) in 82 formalin-fixed hepatocellular carcinoma tissues by immunohistochemistry and determined the sequence of the dbpA promoter region in 42 frozen hepatocellular carcinoma tissues. We examined the relationship between these findings and the clinicopathologic factors of hepatocellular carcinoma patients. Results: DbpA expression was associated with the advanced stages of hepatocellular carcinoma, and the cases with the nuclear dbpA expression had a poor prognosis. DbpA contributed more significantly to this association than YB-1. Furthermore, the T-to-G transversion in the dbpA promoter region was related to the nuclear localization of dbpA. Conclusion: DbpA was a more significant prognostic marker of hepatocellular carcinoma than YB-1. The T-to-G transversion in the dbpA promoter region was suggested to be a predisposing factor for the progression of hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=27144557255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144557255&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1027

DO - 10.1158/1078-0432.CCR-05-1027

M3 - Article

C2 - 16243807

AN - SCOPUS:27144557255

VL - 11

SP - 7354

EP - 7361

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -